Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01859715 · ClinicalTrials.gov registry record · NA
Emergency Department (ED) Drug Interaction in Emergency Department Patients
A NA study of Drug Interactions, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 502
- Enrollment target
- 1
- Study location
NCT01859715: Completed NA study of Drug Interactions, sponsored by University of Colorado, Denver.
NCT01859715 is a NA study of Drug Interactions that has completed, run by University of Colorado, Denver. The registered enrollment target is 502 participants, below the 646-participant average among 6 other Drug Interactions trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01859715, a NA study of Drug Interactions, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 502 participants
- Enrollment target
- 1
- Study location
Study Summary
This study examines how hepatic cytochrome CYP2D6 drug interactions affects the efficacy of oxycodone, hydrocodone, and ondansetron in Emergency Department (ED) patients.
Primary Outcome
Clinically significant visual analogue scale (VAS; a measure of adult pain and nausea on a scale of 1-100 millimeters for increasing symptoms of pain and nausea) for patients who were administered either oxycodone, hydrocodone/acetaminophen, or ondansetron in the ED. Clinically significant change was defined as 13mm change on the VAS from baseline (when first VAS was completed) to 90 minutes following drug administration in the ED.
Conditions Studied
Interventions
- DRUG Oxycodone
- DRUG Ondansetron
- DRUG Hydrocodone
Study Locations (1)
Colorado
- University of Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-02 |
| Phase | NA |
What the finished NCT01859715 record still lists
NCT01859715 is an interventional study that assigns participants to a tested intervention. The registered 502 participants enrollment target is mid-sized for trials with a published cap, below the 646-participant average among 6 other Drug Interactions trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Drug Interactions appearing as the primary indexed condition, and to 3 interventions - of which Oxycodone is the first listed.
NCT01859715 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT01859715 about?
NCT01859715 is a clinical study titled "Emergency Department (ED) Drug Interaction in Emergency Department Patients". This study examines how hepatic cytochrome CYP2D6 drug interactions affects the efficacy of oxycodone, hydrocodone, and ondansetron in Emergency Department (ED) patients.
What is the current status of trial NCT01859715?
This trial is currently completed. It is a NA study. The enrollment target is 502 participants. The study started on 2012-06. Estimated completion is 2013-02.
What conditions does trial NCT01859715 study?
This clinical trial studies the following conditions: Drug Interactions.
What interventions are being tested in trial NCT01859715?
The interventions under investigation include: Oxycodone (DRUG), Ondansetron (DRUG), Hydrocodone (DRUG).
Who is sponsoring clinical trial NCT01859715?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01859715 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Interactions
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Shared Decision for Drug Interactions in Oral Anticoagulation
RECRUITING · NA
-
Opioid Drug Interaction Study
RECRUITING · Phase 1
-
LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering
RECRUITING · Phase 4
-
Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects
COMPLETED · Phase 1
-
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
COMPLETED · Phase 1
-
Open-Label, Multiple-Dose, Non-Randomized Study to Assess Drug-Drug Interactions of Proellex® in Female Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
- NCT05143931 · 503 participants · NA
Avoid and Resist Strategies for Weight Management
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia